Immatics (IMTX) Other Non-Current Liabilities (2019 - 2023)
Immatics recorded quarterly Other Non-Current Liabilities of $4303.8 in Q4 2023, down 80.23% quarter-over-quarter from $21771.8 in Q3 2023, and down 89.96% year-over-year from $42850.4 in Q4 2022.
Immatics' Other Non-Current Liabilities history runs 5 years deep, the most recent figure standing at $4303.8 for Q4 2023.
- In Q4 2023, Other Non-Current Liabilities fell 89.96% year-over-year to $4303.8; the TTM figure through Dec 2023 stood at $4303.8 (down 89.96% YoY), while the FY2023 annual figure was $4303.8, down 90.28% from the prior year.
- Other Non-Current Liabilities came in at $4303.8 for Q4 2023 at Immatics, down from $21771.8 in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $46.7 million in Q3 2021 to a low of $4303.8 in Q4 2023.
- A 5-year average of $7.9 million and a median of $66831.8 in 2022 frame the typical range for Other Non-Current Liabilities.
- Across the five-year window, Other Non-Current Liabilities jumped 1396.13% in 2020 and slumped 99.88% in 2022, its largest moves.
- Immatics' Other Non-Current Liabilities stood at $2.3 million in 2019, then soared by 1396.13% to $34.5 million in 2020, then plunged by 99.77% to $77790.0 in 2021, then sank by 44.92% to $42850.4 in 2022, then plunged by 89.96% to $4303.8 in 2023.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $4303.8, $21771.8, and $28312.0 for Q4 2023, Q3 2023, and Q2 2023 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Immatics | 1.80 Bn | 1.80 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 4,303.76 |
| Sep 30, 2023 | 21,771.81 |
| Jun 30, 2023 | 28,312.03 |
| Mar 31, 2023 | 35,420.28 |
| Dec 31, 2022 | 42,850.39 |
| Sep 30, 2022 | 55,455.09 |
| Jun 30, 2022 | 62,956.34 |
| Mar 31, 2022 | 70,707.28 |
| Dec 31, 2021 | 77,790.02 |
| Sep 30, 2021 | 46.66 Mn |
| Jun 30, 2021 | 13.07 Mn |
| Mar 31, 2021 | 14.14 Mn |
| Dec 31, 2020 | 34.51 Mn |
| Dec 31, 2019 | 2.31 Mn |